share_log

賽生藥業：根據收購守則規則3.8刊發的公告

SCICLONE PHARMA: ANNOUNCEMENT PURSUANT TO RULE 3.8 OF THE TAKEOVERS CODE

Hong Kong Stock Exchange ·  Apr 23 10:23
Summary by Moomoo AI
賽生藥業控股有限公司於2024年4月23日發布公告，提及Silver Pegasus Investment Limited計劃以協議安排方式將賽生藥業私有化的聯合公告。該公告涉及賽生藥業於2018年及2021年採納的購股權激勵計劃。公告指出，因行使首次公開發售後購股權計劃，賽生藥業已發行新股份7,500股，使得總已發行股份達到628,481,632股。此外，賽生藥業還披露了購股權激勵計劃下的購股權數目，包括已授出且已歸屬的購股權。公告中未提及其他未行使的證券、購股權、衍生工具或可轉換或交換為股份的認股權證。賽生藥業的執行董事、首席執行官兼總裁趙宏及其他董事成員對公告內容的準確性承擔責任，並確認公告中無任何遺漏事實。
賽生藥業控股有限公司於2024年4月23日發布公告，提及Silver Pegasus Investment Limited計劃以協議安排方式將賽生藥業私有化的聯合公告。該公告涉及賽生藥業於2018年及2021年採納的購股權激勵計劃。公告指出，因行使首次公開發售後購股權計劃，賽生藥業已發行新股份7,500股，使得總已發行股份達到628,481,632股。此外，賽生藥業還披露了購股權激勵計劃下的購股權數目，包括已授出且已歸屬的購股權。公告中未提及其他未行使的證券、購股權、衍生工具或可轉換或交換為股份的認股權證。賽生藥業的執行董事、首席執行官兼總裁趙宏及其他董事成員對公告內容的準確性承擔責任，並確認公告中無任何遺漏事實。
Caisang Pharmaceutical Holdings Limited issued a notice on 23 April 2024, mentioning the joint announcement that Silver Pegasus Investment Limited plans to privatize its pharmaceutical business by agreement. The announcement relates to the Share Option Incentive Scheme adopted by Sai Sai Pharma in 2018 and 2021. The announcement notes that as a result of the initial public offering post-IPO share option plan, Saisheng Pharmaceuticals has issued 7,500 new shares, bringing the total issued shares to 628,481,632 shares. In addition, Caisang Pharmaceuticals also disclosed the number of warrants under the Share Rights Incentive Program, including those granted and vested. No other outstanding securities, call options, derivatives or warrants convertible or exchangeable into shares are mentioned in the announcement. The Executive Director, Chief Executive Officer and President of Sai Sang Pharmaceuticals, Zhao Hong and other members of the Board are responsible for the accuracy of the contents of the announcement and confirm that there are no omissions in the announcement.
Caisang Pharmaceutical Holdings Limited issued a notice on 23 April 2024, mentioning the joint announcement that Silver Pegasus Investment Limited plans to privatize its pharmaceutical business by agreement. The announcement relates to the Share Option Incentive Scheme adopted by Sai Sai Pharma in 2018 and 2021. The announcement notes that as a result of the initial public offering post-IPO share option plan, Saisheng Pharmaceuticals has issued 7,500 new shares, bringing the total issued shares to 628,481,632 shares. In addition, Caisang Pharmaceuticals also disclosed the number of warrants under the Share Rights Incentive Program, including those granted and vested. No other outstanding securities, call options, derivatives or warrants convertible or exchangeable into shares are mentioned in the announcement. The Executive Director, Chief Executive Officer and President of Sai Sang Pharmaceuticals, Zhao Hong and other members of the Board are responsible for the accuracy of the contents of the announcement and confirm that there are no omissions in the announcement.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more